angiotensin II receptor blockers, losartan
DISEASE INTERVENTION COMPARISON RESULTS
J Am Coll Cardiol. 2005 Mar 1;45(5):705-11 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, persistent, hypertension, primary The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is better Than
beta-blockers
To reduce cardiovascular events (composite of cardiovascular mortality, stroke, and myocardial infarction): 36/171 patients with losartan VS 67/171 patients with B-blokers, at aprox 4 years
Lancet. 2000 May 6;355(9215):1582-1587 Randomized Controlled Trial
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is equal Than
angiotensin converting enzyme (ACE) inhibitors, captopril
To reduce, at about 2 years, all-cause mortality: 11.7% losartan VS 10.4% captopril. Losartan had less adverse effects: 9.7% discontinued Tt VS 14.7% with captopril, mainly becuase cought
Lancet. 1997 Mar 15;349(9054):747-52 Randomized Controlled Trial
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is equal Than
angiotensin converting enzyme inhibitors (ACEI), captopril
To avoid worsening renal dysfunction, defined as a persistent increase in serum creatinine: 10.5% in each group. There was a significant difference in mortality, secondary end-point, not confirmed in the next trial ELITE-II.
Lancet. 2002 Mar 23;359(9311):995-1003 Randomized Controlled Trial, Multicenter Study
IN hypertension, primary The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is better Than
beta blockers, atenolol
To reducing major cardiovascular events (death, myocardial infarction, or stroke): 23.8 per 1000 PYs in intv. / 27.9 per 1000 PYs in cont. Losartan reduces strokes and cardiovascular deaths but not myocardial infarction.
J Am Coll Cardiol. 2005 Mar 1;45(5):712-9 Randomized Controlled Trial, Multicenter Study
IN hypertension, primary, ventricular hypertrophy, atrial fibrillation The Use of
angiotensin II receptor blockers, losartan
As Treatment, Chronic
Is better Than
beta-blockers
To prevent development of new-onset atrial fibrillation: AF occurred in 6.8/1,000 person-years with losartan VS 10.1 with B-blockers.